4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth.

4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth.
复制标题

DOI:
10.1021/jm401752p
复制
发表时间:
2014-02-13
影响因子:
7.3
通讯作者:
Maloney DJ
Maloney DJ
中科院分区:
医学1区
文献类型:
--
作者:
Foley TL;Rai G;Yasgar A;Daniel T;Baker HL;Attene-Ramos M;Kosa NM;Leister W;Burkart MD;Jadhav A;Simeonov A;Maloney DJ

文献摘要

参考文献

被引文献

相似文献

4'-磷酸酯酰乙胺基转移酶 (PPTase) 催化对细菌细胞活力和毒力至关重要的翻译后修饰。我们介绍了 2-吡啶基-N-(4-芳基)哌嗪-1-硫代硫酰胺的发现和药物化学优化,该药物对细菌 Sfp-PPTase 具有亚微摩尔抑制作用,但对人类直系同源物没有活性。此外,此类化合物在人体细胞中不存在快速细胞毒性反应的情况下具有抗菌活性。该系列的高级类似物 ML267 (55),被发现以亚致死剂量应用于枯草芽孢杆菌时,可减弱 Sfp-PPTase 依赖性代谢物的产生。其他测试显示对耐甲氧西林金黄色葡萄球菌具有抗菌活性,化学遗传学研究表明外排是大肠杆菌的耐药机制。此外,我们重点介绍了化合物 55 的体外吸收、分布、代谢和排泄以及体内药代动力学特征,以进一步证明这种小分子抑制剂的潜在用途。
4′-Phosphopantetheinyl transferases (PPTases) catalyze a post-translational modification essential to bacterial cell viability and virulence. We present the discovery and medicinal chemistry optimization of 2-pyridinyl-N-(4-aryl)piperazine-1-carbothioamides, which exhibit submicromolar inhibition of bacterial Sfp-PPTase with no activity toward the human orthologue. Moreover, compounds within this class possess antibacterial activity in the absence of a rapid cytotoxic response in human cells. An advanced analogue of this series, ML267 (55), was found to attenuate production of an Sfp-PPTase-dependent metabolite when applied to Bacillus subtilis at sublethal doses. Additional testing revealed antibacterial activity against methicillin-resistant Staphylococcus aureus, and chemical genetic studies implicated efflux as a mechanism for resistance in Escherichia coli. Additionally, we highlight the in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetic profiles of compound 55 to further demonstrate the potential utility of this small-molecule inhibitor.
DOI: 10.1111/j.1365-2958.2011.07942.x
发表时间: 2012-01
影响因子: 3.6
作者:
Alonzo F 3rd;Benson MA;Chen J;Novick RP;Shopsin B;Torres VJ
通讯作者: Torres VJ
DOI: 10.1038/nchembio706
发表时间: 2005-06-01
影响因子: 14.8
作者:
Ferreras, JA;Ryu, JS;Quadri, LEN
通讯作者: Quadri, LEN
大肠杆菌K-12的构造框架,单基因敲除突变体:Keio Collection。
DOI: 10.1038/msb4100050
发表时间: 2006
影响因子: 9.9
作者:
通讯作者: --
DOI: 10.1517/17460441.2012.708335
发表时间: 2012-09
影响因子: 6.3
作者:
Foley TL;Simeonov A
通讯作者: Simeonov A
DOI: 10.1016/s0040-4039(98)00504-8
发表时间: 1998-05-07
影响因子: 1.8
作者:
Lam, PYS;Clark, CG;Combs, A
通讯作者: Combs, A